Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Eugia Steriles receives EIR from USFDA for new injectable facility
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
The study observed 2,648 girls, of which 2,300 completed the standard 45-day programme
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Subscribe To Our Newsletter & Stay Updated
